Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M4112 in advanced solid tumors
NCT03306420Phase 1Terminated
- Sponsor
- EMD Serono
- Start
- Oct 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of M4112 in solid tumor (5 arms), sponsored by EMD Serono. Primary endpoints: Dose Limiting Toxicities, Treatment Emergent Adverse Events and Treatment Related Adverse Events and 4 more. Started Oct 2017; status: terminated.
02
Drugs
M4112
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03306420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03306420.